



Cardiovascular Diseases and COVID-19

Guest Editors:

Dr. Aneta Aleksova

Department of Medical Surgical
and Health Science, University of
Trieste, Italy and Cardiovascular
Department, Azienda Sanitaria
Universitaria Giuliano Isontina
(ASUGI), 34148 Trieste, Italy

Dr. Milijana Janjušević

1. Department of Medical Surgical
and Health Science, University of
Trieste, Trieste, Italy
2. Cardiovascular Department,
Azienda Sanitaria Universitaria
Giuliano Isontina (ASUGI), 34148
Trieste, Italy

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editors

Dear Colleagues,

At the outset of the COVID-19 pandemic, it immediately became apparent that individuals with previous cardiovascular diseases were at higher risk for severe forms of COVID-19 and adverse outcomes. Remarkably, recent studies have indicated that both symptomatic and asymptomatic SARS-CoV-2 infection has a negative impact on cardiovascular health and is associated with mortality during the period after COVID-19, which means that SARS-CoV-2 infection should be an important risk factor as well.

This Special Issue welcomes original research articles and state-of-the-art reviews. Papers should provide novel data or gather current knowledge regarding the relationship between cardiovascular diseases and COVID-19, with a special focus on pathophysiological aspects of COVID-19 on cardiovascular health, covering (but not be limited to) molecular mechanisms that support deterioration processes such as inflammation, oxidative stress and endothelial dysfunction, useful clinical aspects related to cardiovascular diagnosis injuries, more accurate risk stratification, and finally therapeutic approaches in these specific circumstances.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)